KalVista Pharmaceuticals, Inc.
KALV
$13.16
$0.171.31%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -52.23M | -48.51M | -42.27M | -40.44M | -44.65M |
| Total Depreciation and Amortization | 261.00K | 229.00K | 227.00K | 224.00K | 219.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 62.00K | 10.01M | 2.19M | 2.31M | 12.72M |
| Change in Net Operating Assets | 11.54M | 5.59M | 213.00K | -2.31M | 16.61M |
| Cash from Operations | -40.36M | -32.68M | -39.64M | -40.22M | -15.11M |
| Capital Expenditure | -281.00K | -24.00K | -108.00K | -21.00K | -15.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.05M | 8.54M | 48.78M | 37.18M | -126.17M |
| Cash from Investing | -3.33M | 8.52M | 48.67M | 37.16M | -126.19M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.85M | 56.54M | 295.00K | 3.00M | 96.98M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.81M | 95.23M | -- | -- | 53.12M |
| Cash from Financing | 4.66M | 151.77M | 295.00K | 3.00M | 150.10M |
| Foreign Exchange rate Adjustments | 3.36M | -1.25M | 407.00K | 117.00K | -74.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -35.67M | 126.36M | 9.73M | 59.00K | 8.73M |